<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121650">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519063</url>
  </required_header>
  <id_info>
    <org_study_id>1005006779</org_study_id>
    <secondary_id>P50AA012870</secondary_id>
    <nct_id>NCT01519063</nct_id>
  </id_info>
  <brief_title>Naltrexone and Memantine Effects on Alcohol Drinking Behaviors</brief_title>
  <official_title>Glutamate-opioid Interactions in Alcohol Drinking Behaviors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the combined effects of the study medications
      naltrexone and memantine on alcohol drinking behaviors. Participants will be randomized to
      receive a combination of these medications over a one week period and then participate in a
      laboratory session. During this session, participants are given an initial drink of alcohol
      followed by the choice to drink up to 12 more drinks over a three-hour period. These
      medications are hypothesized to reduce craving and number of drinks consumed prior to and
      after exposure to the initial drink of alcohol and during the three hour drinking period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of drinks consumed</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stimulation and sedation responses to alcohol</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Alcohol Drinking</condition>
  <arm_group>
    <arm_group_label>Naltrexone and memantine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Naltrexone and memantine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with naltrexone and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone and memantine</intervention_name>
    <description>Naltrexone 50mg memantine 20mg</description>
    <arm_group_label>Naltrexone and memantine</arm_group_label>
    <other_name>memantine's brand name is Namenda</other_name>
    <other_name>naltrexone's brand name is Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone and Placebo</intervention_name>
    <description>Naltrexone 50 mg Placebo</description>
    <arm_group_label>Naltrexone and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 21-55

          -  Able to read English at 6th grade level or higher and to complete study evaluations

          -  Regular alcohol drinker

        Exclusion Criteria:

          -  Individuals who are seeking alcohol treatment

          -  Medical conditions that would contraindicate the use of study medication

          -  Regular use of other substances
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suchitra Krishnan-Sarin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Franco, B.A.</last_name>
    <phone>203 974-7679</phone>
    <email>nicholas.franco@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana Cavallo, Ph.D.</last_name>
    <phone>203 974-7607</phone>
    <email>dana.cavallo@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sac, Cmhc</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 23, 2016</lastchanged_date>
  <firstreceived_date>January 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Drinking</keyword>
  <keyword>Drinkers</keyword>
  <keyword>Alcohol Drinking</keyword>
  <keyword>Memantine</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Alcohol Abuse</keyword>
  <keyword>Alcohol-Related Disorders</keyword>
  <keyword>Ethanol</keyword>
  <keyword>Alcoholism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcohol Drinking</mesh_term>
    <mesh_term>Drinking Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
